Attached files
| file | filename |
|---|---|
| EX-99.1 - FENNEC PHARMACEUTICALS INC. | v194111_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of
report (Date of earliest event reported) August 13,
2010
|
Adherex Technologies
Inc.
|
|
(Exact
Name of Registrant as Specified in Its
Charter) |
|
Canada
|
001-32295
|
20-0442384
|
||
|
(State
or Other Jurisdiction
of
Incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
501
Eastowne Drive, Suite 140, Chapel Hill , North Carolina 27514
(Address
of Principal Executive Offices) (Zip Code)
919-636-4530
(Registrant’s
Telephone Number, Including Area Code)
Not
applicable.
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction
A.2. below):
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Item
2.02 Results
of Operations and Financial Condition.
On August
13, 2010, Adherex Technologies, Inc. issued a press release announcing financial
results for its fiscal quarter ended June 30, 2010. The full text of
the press release is furnished as Exhibit 99.1.
Item
9.01 Financial
Statements and Exhibits
Exhibits
|
99.1
|
Press
Release issued by Adherex Technologies, Inc. dated August 13,
2010.
|
Except
for historical information herein, matters set forth in this report are
forward-looking within the meaning of the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995, including statements about the
Company’s commercial and technology progress and future financial
performance. These forward-looking statements are identified by the use of words
such as "commences,” “continue,” “expects,” “believes,”
and “intends,” among others. Forward-looking statements in this press
release are subject to certain risks and uncertainties inherent in the Company's
business that could cause actual results to vary, including such risks
that regulatory clinical and guideline developments may
change, scientific data may not be sufficient to meet regulatory standards
or receipt of required regulatory clearances or approvals, clinical results
may not be replicated in actual patient settings, protection offered
by the Company's patents and patent applications may be challenged,
invalidated or circumvented by its competitors, the available market
for the Company's products will not be as large as
expected, the Company's products will not be able to penetrate one or
more targeted markets, revenues will not be sufficient to fund further
development and clinical studies, the Company may not meet its future
capital needs, and its ability to obtain additional funding, as well as
uncertainties relative to varying product formulations and a multitude of
diverse regulatory and marketing requirements in different countries and
municipalities, and other risks detailed from time to time in the Company's
filings with the Securities and Exchange Commission including the annual report
on Form 10-K for the year ended December 31, 2009. Adherex Technologies,
Inc. disclaims any obligation to update these forward-looking statements except
as required by law.
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
Dated: August
13, 2010
|
Adherex
Technologies Inc.
|
||
|
By:
|
/s/ Robert Andrade
|
||
|
Chief
Financial Officer
|
|||
3